A review of the symptomatic management of malignant gliomas in adults

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 4, 2013, Pages 424-429

  Shah, Umang ^a   Morrison, Tara ^b  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; BEVACIZUMAB; CARBAMAZEPINE; DALTEPARIN; DAPSONE; DEXAMETHASONE; DEXAMPHETAMINE; DONEPEZIL; ETIRACETAM; FONDAPARINUX; GABAPENTIN; HARKOSERIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEMANTINE; METHYLPHENIDATE; METOCLOPRAMIDE; MODAFINIL; ONDANSETRON; OXCARBAZEPINE; PEMOLINE; PENTAMIDINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TEMOZOLOMIDE; TINZAPARIN; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ANEMIA; ANTICONVULSANT THERAPY; BLEEDING; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE ASSOCIATION; DRUG HALF LIFE; FATIGUE; GASTRITIS; GLIOBLASTOMA; HICCUP; HUMAN; HYPOXEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSOMNIA; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOADING DRUG DOSE; LUNG EMBOLISM; MOLECULAR GENETICS; MORBIDITY; MYOPATHY; NAUSEA; OSTEOPENIA; OVERALL SURVIVAL; PEPTIC ULCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SEIZURE; TEMPORAL LOBE; THORAX RADIOGRAPHY; TREMOR; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 84877974367     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0057     Document Type: Review

References (33)

1. Central Brain Tumor Registry of the United States (2012). CBTRUS Statistical report: Primary Brain and Central Nervous System Tumors diagnosed in the United States in 2004-2008. February 2012. Available at: http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS-Report-2004-2008-3-23-2012.pdf. Accessed September 5, 2012.
2. Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol 2011;13:413-426.
3. Rudà R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol 2010;22:611-620.
4. Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev 2009;32:275-285.
5. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893.
6. Nabors LB, Ammirati M, Bierman PJ, et al. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2013. Available at: NCCN.org. Accessed February 28, 2013.
7. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409.
8. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011;77:1156-1164.
9. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009;73:1207-1213.
10. Usery JB, Michael LM II, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 2010;99:251-260.
11. Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain surgery. J Neurooncol 2011;101:101-106.
12. Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 2011;104:205-214.
13. Bähr O, Hermisson M, Rona S, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien) 2012;154:229-235.
14. Sisodiya SM, Lint WR, Harding BN, et al. Drug resistance in epilepsy: human epilepsy. Novartis Found Symp 2002;243:167-174; discussion 174-179, 180-185.
15. Ruda R, Trevisan E, Magliola U, et al. Efficacy of radiation on epileptic seizures of grade 2 and 3 gliomas: a retrospective study [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 2074.
16. Del Maestro RF, Megyesi JF, Farrell CL. Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 1990;17:177-183.
17. Klatzo I. Presidential address. Neuropathological aspects of brain edema. J Neuropathol Exp Neurol 1967;26:1-14.
18. Gerstner ER, Duda DG, di Tomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229-236.
19. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41-44.
20. Colby C, McAfee S, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:897-902.
21. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4889-4894.
22. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010;8:221-227.
23. Streiff MB, Bockenstedt PL, Cataland SR, et al. NCCN Clinical Practice Guidelines in Oncology: Venous Thromboembolic Disease. Version 1.2013. Available at: NCCN.org. Accessed February 28, 2013.
24. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000;160:2327-2332.
25. Korana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919-4926.
26. Robins HI, O'Neill A, Gilbert M, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008;62:227-233.
27. Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009;95:129-134.
28. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8:1959-1965.
29. Litofsky NS, Farace E, Anderson F Jr, et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004;54:358-366.
30. Shaw EG, Rosdahl R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood and quality of life. J Clin Oncol 2006;24:1415-1420.
31. Wefel JS, Shook S, Brown PD, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy (WBRT): first report of RTOG 0614, a placebo-controlled, double-blind, randomized trial. Abstracts from the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 15-18, 2012, Washington, D.C. Neuro Oncol 2012;14(Suppl 6):vi61-64.
32. Ettinger DS, Armstrong DK, Barbour S, et al. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1, 2013. Available at: NCCN.org. Accessed February 22, 2013.
33. Saylor MS, Smetana RF. Potential for drug-drug interactions in treating cancer-related nausea and vomiting. J Oncol Pharm Pract 2010;17:403-408.